Treprostinil (diethanol<wbr/>amine salt)

Treprostinil (diethanolamine salt)

CAT N°: 11927
Price:

From 162.00 137.70

Treprostinil is a derivative of prostaglandin I2 (PGI2/prostacyclin; Item No. 18220) and an agonist of PGI2, PGD2, and PGE2 receptors IP2, DP2, and EP2.{49660,49661} It binds selectively to IP2, DP2, and EP2 over EP1, EP3, and EP4 receptors with Ki values of 32, 4.4, 3.6, 212, 2,505, and 826 nM, respectively, in radioligand binding assays.{49661} Treprostinil inhibits LPS-induced production of TNF-?, IL-1?, IL-6, and granulocyte macrophage colony-stimulating factor (GM-CSF) in isolated human alveolar macrophages when used at a concentration of 200 ng/ml.{12665} It also prevents LPS-induced nuclear translocation and activation of NF-?B in the same cells. Treprostinil relaxes isolated small pulmonary arteries and veins precontracted with the thromboxane A2 (TP) receptor antagonist U-46619 (Item No. 16450), an effect that can be blocked by IP receptor antagonists in the arteries and reduced by IP receptor antagonists in the veins{49662}. It reduces right ventricular systolic pressure, but not right ventricular hypertrophy, compared to hypoxic and sham control animals in a mouse model of chronic hypoxic pulmonary hypertension.{49663} Formulations containing treprostinil have been used in the treatment of primary pulmonary hypertension.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-acetic acid, diethanolamine salt
  • Correlated keywords
    • 2,2′-iminobis[ethanol] UT15C UT-15C diethanol amine I A PGI IP DP EP 2 3 4 TNF? IL1? IL6 radio ligand GMCSF NF?B U46619 Remodulin
  • Product Overview:
    Treprostinil is a derivative of prostaglandin I2 (PGI2/prostacyclin; Item No. 18220) and an agonist of PGI2, PGD2, and PGE2 receptors IP2, DP2, and EP2.{49660,49661} It binds selectively to IP2, DP2, and EP2 over EP1, EP3, and EP4 receptors with Ki values of 32, 4.4, 3.6, 212, 2,505, and 826 nM, respectively, in radioligand binding assays.{49661} Treprostinil inhibits LPS-induced production of TNF-?, IL-1?, IL-6, and granulocyte macrophage colony-stimulating factor (GM-CSF) in isolated human alveolar macrophages when used at a concentration of 200 ng/ml.{12665} It also prevents LPS-induced nuclear translocation and activation of NF-?B in the same cells. Treprostinil relaxes isolated small pulmonary arteries and veins precontracted with the thromboxane A2 (TP) receptor antagonist U-46619 (Item No. 16450), an effect that can be blocked by IP receptor antagonists in the arteries and reduced by IP receptor antagonists in the veins{49662}. It reduces right ventricular systolic pressure, but not right ventricular hypertrophy, compared to hypoxic and sham control animals in a mouse model of chronic hypoxic pulmonary hypertension.{49663} Formulations containing treprostinil have been used in the treatment of primary pulmonary hypertension.

We also advise you